Egetis Therapeutics AB (publ) (STO:EGTX)

Sweden flag Sweden · Delayed Price · Currency is SEK
4.995
+0.245 (5.16%)
Mar 4, 2026, 5:29 PM CET
5.16%
Market Cap 1.97B
Revenue (ttm) 62.40M
Net Income (ttm) -342.50M
Shares Out 395.16M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE 8.19
Dividend n/a
Ex-Dividend Date n/a
Volume 447,861
Average Volume 753,509
Open 4.765
Previous Close 4.750
Day's Range 4.705 - 4.995
52-Week Range 3.025 - 7.070
Beta 1.13
RSI 47.43
Earnings Date Feb 26, 2026

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 40
Stock Exchange Nasdaq Stockholm
Ticker Symbol EGTX
Full Company Profile

Financial Performance

In 2025, Egetis Therapeutics AB's revenue was 62.40 million, an increase of 35.36% compared to the previous year's 46.10 million. Losses were -342.50 million, -0.32% less than in 2024.

Financial Statements

News

There is no news available yet.